Rossari Biotech Intrinsic Value
Rossari Biotech (ROSSARI) median intrinsic value is ₹1037.70 from 9 valuation models (range ₹212–₹1297), vs current price ₹518.85 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Browse ROSSARI financial statements for revenue, profit, balance sheet and cash flow data.
ROSSARI Valuation Methods Summary — DCF, Graham Number & P/E
Rossari Biotech intrinsic value across 9 models vs current price ₹518.85 — upside/downside and value range per method. For current market price and key ratios, visit Rossari Biotech stock price NSE.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹398.40 | ₹318.72 - ₹478.08 | -23.2% | EPS: ₹33.20, Sector P/E: 12x |
| Book Value Method | asset | ₹1211.82 | ₹1090.64 - ₹1333.00 | +133.6% | Book Value/Share: ₹1211.82, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹1037.70 | ₹933.93 - ₹1141.47 | +100.0% | Revenue/Share: ₹2560.00, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹1037.70 | ₹933.93 - ₹1141.47 | +100.0% | EBITDA: ₹388.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹1297.12 | ₹1037.70 - ₹1556.54 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹212.48 | ₹191.23 - ₹233.73 | -59.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹273.57 | ₹246.21 - ₹300.93 | -47.3% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹1037.70 | ₹933.93 - ₹1141.47 | +100.0% | ROE: 13.8%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹951.43 | ₹856.29 - ₹1046.57 | +83.4% | EPS: ₹33.20, BVPS: ₹1211.82 |
ROSSARI Intrinsic Value vs Market Price — All Valuation Models
Rossari Biotech fair value range ₹212–₹1297 vs current market price ₹518.85 across 9 valuation models. Also explore ROSSARI share price data to track price trends across different timeframes.
ROSSARI Intrinsic Value Analysis — Undervalued or Overvalued?
Rossari Biotech median intrinsic value ₹1037.70, current price ₹518.85 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of ROSSARI?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Rossari Biotech (ROSSARI) is ₹1037.70 (median value). With the current market price of ₹518.85, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹212.48 to ₹1297.12, indicating ₹212.48 - ₹1297.12.
Is ROSSARI undervalued or overvalued?
Based on our multi-method analysis, Rossari Biotech (ROSSARI) appears to be trading below calculated value by approximately 100.0%.
ROSSARI Financial Health — Key Ratios vs Industry Benchmarks
Rossari Biotech financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 7.49 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 13.8% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 11.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.23x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
ROSSARI Cash Flow Quality — Operating & Free Cash Flow
Rossari Biotech operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹137 Cr | ₹46 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹43 Cr | ₹-9 Cr | Positive Operating Cash Flow | 6/10 |
| March 2023 | ₹152 Cr | ₹62 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹29 Cr | ₹-121 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹48 Cr | ₹30 Cr | Positive Free Cash Flow | 8/10 |